Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity	Name	nf	enti	tν
----------------	------	----	------	----

GALE PACIFIC LIMITED

ABN

80 082 263 778

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

†Class of *securities issued or to be issued

Performance Rights

- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 913,000 Performance Rights to the Group Managing Director (Group MD Performance Rights)
- 2,109,000 Performance Rights to Senior Executives (Executive Performance Rights)
- 3 Principal terms of the

 +securities (e.g. if options,
 exercise price and expiry date;
 if partly paid +securities, the
 amount outstanding and due
 dates for payment; if
 +convertible securities, the
 conversion price and dates for
 conversion)
- Each Performance Right grants a right to acquire a fully paid ordinary share in the Company subject to satisfaction of relevant performance conditions. The performance conditions are based on the Company's earnings per share and continuation of employment over a performance period of 3 years.
- Performance Rights have been granted at no cost to the Employees.
- 3. The date of grant of the Performance Rights is 9 October 2015.
- 4. There is no amount payable by an Employee upon vesting of a Performance Right.
- An unvested Performance Right will lapse upon the earliest to occur of:
 - a. the Participant ceasing to be an

employee of a Group Company before a Performance Right has vested by reason of his death, disability, bona fide redundancy or other reason approved by the Board, except to the extent to which the Board determines that such Performance Rights will be deemed to vest;

- b. the Participant ceasing to be an employee of a Group Company for any reason other than set out in the paragraph immediately above:
- the Participant attempting an unauthorised transfer of the Performance Right in accordance with Plan rules;
- d. the Participant failing to meet the Performance Conditions in the prescribed period; or
- e. the expiry date of the Performance Rights, being 1 December 2018.
- 4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

No. Performance Rights will not be quoted or rank equally with any class of quoted securities. However, fully paid ordinary shares issued on the vesting of the Performance Rights will be quoted. Under the terms of issue of the Performance Rights, those shares will rank:

- For any dividend with a record date (for determining entitlements to it) which is the same as or after the date of issue of the shares equally with the fully paid ordinary shares then on issue; and
- From the date of issue of the shares, in all other respects, equally with the fully paid ordinary shares then on issue.

Nil			

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6 Purpose of the issue The Group MD Performance Rights are (If issued as consideration for issued to the Group Managing Director the acquisition of assets, clearly under the Company's Performance Rights Share Plan as approved by shareholders at identify those assets) the Company's Annual General Meeting on 28 November 2014 as a standard component of remuneration and is intended to comprise the long term incentive component of the Group Managing Director's remuneration. The Executive Performance Rights are issued to Senior Executives under the Company's Performance Rights Share Plan as approved by shareholders at the Company's Annual General Meeting on 26 October 2012 as a standard component of remuneration and is intended to comprise the long term incentive component of the Senior Executives' remuneration. 6a No Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b -6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed Nil 6c Number of *securities issued without security holder approval under rule 7.1 Nil 6d Number of +securities issued with security holder approval under rule 7.1A N/A 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 3,022,000 Performance Rights 6f Number of +securities issued under an exception in rule 7.2

6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
7	*Issue dates	9 October 2015	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	3 Colober 2010	
	Cross reference: item 33 of Appendix 3B.		
		Number	
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	297,474,396	+Class Fully paid ordinary shares
		Number	la:
0	Number and +class of all	5,386,138	+Class
9	*securities not quoted on ASX (including the *securities in section 2 if applicable)	5,300,130	Performance Rights
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Rank equally	
Part	2 - Pro rata issue		
11	Is security holder approval required?	N/A	
40	le the leave was surely to the	NI/A	1
12	Is the issue renounceable or non-renounceable?	N/A	

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their	
	entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
	Cross reference. rate 1.11.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
00	English to the second s	NI/A
23	Fee or commission payable to the broker to the issue	N/A
0.4	Amount of any language of the	NI/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A

26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell part of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A
	t 3 - Quotation of sec	
34	Type of *securities (tick one)	
(a)	*Securities described in Par	rt 1
(b)		end of the escrowed period, partly paid securities that become fully paid, when restriction ends, securities issued on expiry or conversion of

Entities that have ticked box 34(a)

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Additional securities forming a new class of securities

Tick to docum	o indicate you are providing the information nents	ion or
35		securities, the names of the 20 largest holders of and the number and percentage of additional ders
36		securities, a distribution schedule of the additional imber of holders in the categories
37	A copy of any trust deed for	the additional *securities
Enti	ties that have ticked box 3	4(b)
38	Number of *securities for which *quotation is sought	N/A
39	*Class of *securities for which quotation is sought	N/A
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	

11	Reason for request for quotation now	N/A
	Example: In the case of restricted securities, end of restriction period	
	(if issued upon conversion of another *security, clearly identify that other *security)	

42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Number	+Class
N/A	N/A

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the †securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

SOPHIE KARZIS
Company Secretary
9 October 2015

04/03/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	297,474,396 fully paid ordinary shares	
Add the following:		
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	Nil	
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 		
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil	
"A"	297,474,396	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	44,621,159	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
 Insert number of ⁺equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 	Nil	
• Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	0	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15 Note: number must be same as shown in Step 2	44,621,159	
Subtract "C" Note: number must be same as shown in Step 3	0	
<i>Total</i> ["A" x 0.15] – "C"	44,621,159 [Note: this is the remaining placement capacity under rule 7.1]	

04/03/2013 Appendix 3B Page 11

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A - Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure calculated	from which the placement capacity is	
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items "E"	N/A	
	·	
Step 4: Subtract "E" from ["A" x "D"] capacity under rule 7.1A	to calculate remaining placement	
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.